[{"id":"711f3231-8203-4d68-9608-37223f0f50f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05629949","created_at":"2022-11-29T14:57:17.648Z","updated_at":"2024-07-02T16:35:07.999Z","phase":"Phase 3","brief_title":"A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05629949","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • ALT02 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 474","initiation":"Initiation: 04/29/2020","start_date":" 04/29/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 04/13/2023","study_completion_date":" 04/13/2023","last_update_posted":"2024-04-23"}]